Glutamatergic transmission in schizophrenia: from basic research to clinical practice
PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and...
Gespeichert in:
| Veröffentlicht in: | Current opinion in psychiatry 2012-03, Vol.25 (2), p.96-102 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 2 |
| container_start_page | 96 |
| container_title | Current opinion in psychiatry |
| container_volume | 25 |
| creator | Kantrowitz, Joshua Javitt, Daniel C |
| description | PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.
RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARYAlthough evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored. |
| doi_str_mv | 10.1097/YCO.0b013e32835035b2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5224527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2585551971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4146-11bd3c77b48a8248f91d3b7fa41a87036b39d49476558f0b4bafe61ffac78e763</originalsourceid><addsrcrecordid>eNpdkU1rFTEUhoMo9lr9ByKDG1dT850ZF0K51CoUurELV-EkN-mkZpJrMmPRX9-U1qpdhSTPeTkvD0KvCT4ieFTvv23Pj7DBhDlGByYwE4Y-QRvCFeulUMNTtMGjIL1iUh2gF7VeYYw5oeNzdEApHZUicoMuTuO6wAyLK5fBdkuBVOdQa8ipC6mrdgq_834qLgX40PmS585AbWRx1UGxU7fkzsaQgoXY7QvYJVj3Ej3zEKt7dX8eootPJ1-3n_uz89Mv2-Oz3nLCZU-I2TGrlOEDDJQPfiQ7ZpQHTmBQmEnDxh0fuZJCDB4bbsA7SbwHqwanJDtEH-9y96uZ3c661ApEvS9hhvJLZwj6_58UJn2Zf2pBKRdUtYB39wEl_1hdXXQrb12MkFxeqx4FlwILKRr59hF5ldeSWjs9UsIYYZQ2iN9BtuRai_MPqxCsb63pZk0_ttbG3vxb42Hoj6a_udc5NlP1e1yvXdGTg7hMunnFRGDeU0woZu3W3z5JdgNDD6Tl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>921331322</pqid></control><display><type>article</type><title>Glutamatergic transmission in schizophrenia: from basic research to clinical practice</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Kantrowitz, Joshua ; Javitt, Daniel C</creator><creatorcontrib>Kantrowitz, Joshua ; Javitt, Daniel C</creatorcontrib><description>PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.
RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARYAlthough evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.</description><identifier>ISSN: 0951-7367</identifier><identifier>EISSN: 1473-6578</identifier><identifier>DOI: 10.1097/YCO.0b013e32835035b2</identifier><identifier>PMID: 22297716</identifier><identifier>CODEN: COPPE8</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Animals ; Antipsychotic Agents - therapeutic use ; Biomarkers - metabolism ; Clinical medicine ; Clinical Trials as Topic ; Genetics ; Glutamic Acid - genetics ; Glutamic Acid - metabolism ; Humans ; Mental health care ; Rats ; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenia - genetics ; Schizophrenia - metabolism ; Schizophrenia - physiopathology ; Thalamus - metabolism ; Tranquilizers</subject><ispartof>Current opinion in psychiatry, 2012-03, Vol.25 (2), p.96-102</ispartof><rights>2012 Lippincott Williams & Wilkins, Inc.</rights><rights>Copyright Lippincott Williams & Wilkins Mar 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4146-11bd3c77b48a8248f91d3b7fa41a87036b39d49476558f0b4bafe61ffac78e763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22297716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kantrowitz, Joshua</creatorcontrib><creatorcontrib>Javitt, Daniel C</creatorcontrib><title>Glutamatergic transmission in schizophrenia: from basic research to clinical practice</title><title>Current opinion in psychiatry</title><addtitle>Curr Opin Psychiatry</addtitle><description>PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.
RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARYAlthough evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.</description><subject>Animals</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biomarkers - metabolism</subject><subject>Clinical medicine</subject><subject>Clinical Trials as Topic</subject><subject>Genetics</subject><subject>Glutamic Acid - genetics</subject><subject>Glutamic Acid - metabolism</subject><subject>Humans</subject><subject>Mental health care</subject><subject>Rats</subject><subject>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - genetics</subject><subject>Schizophrenia - metabolism</subject><subject>Schizophrenia - physiopathology</subject><subject>Thalamus - metabolism</subject><subject>Tranquilizers</subject><issn>0951-7367</issn><issn>1473-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1rFTEUhoMo9lr9ByKDG1dT850ZF0K51CoUurELV-EkN-mkZpJrMmPRX9-U1qpdhSTPeTkvD0KvCT4ieFTvv23Pj7DBhDlGByYwE4Y-QRvCFeulUMNTtMGjIL1iUh2gF7VeYYw5oeNzdEApHZUicoMuTuO6wAyLK5fBdkuBVOdQa8ipC6mrdgq_834qLgX40PmS585AbWRx1UGxU7fkzsaQgoXY7QvYJVj3Ej3zEKt7dX8eootPJ1-3n_uz89Mv2-Oz3nLCZU-I2TGrlOEDDJQPfiQ7ZpQHTmBQmEnDxh0fuZJCDB4bbsA7SbwHqwanJDtEH-9y96uZ3c661ApEvS9hhvJLZwj6_58UJn2Zf2pBKRdUtYB39wEl_1hdXXQrb12MkFxeqx4FlwILKRr59hF5ldeSWjs9UsIYYZQ2iN9BtuRai_MPqxCsb63pZk0_ttbG3vxb42Hoj6a_udc5NlP1e1yvXdGTg7hMunnFRGDeU0woZu3W3z5JdgNDD6Tl</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Kantrowitz, Joshua</creator><creator>Javitt, Daniel C</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>5PM</scope></search><sort><creationdate>201203</creationdate><title>Glutamatergic transmission in schizophrenia: from basic research to clinical practice</title><author>Kantrowitz, Joshua ; Javitt, Daniel C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4146-11bd3c77b48a8248f91d3b7fa41a87036b39d49476558f0b4bafe61ffac78e763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biomarkers - metabolism</topic><topic>Clinical medicine</topic><topic>Clinical Trials as Topic</topic><topic>Genetics</topic><topic>Glutamic Acid - genetics</topic><topic>Glutamic Acid - metabolism</topic><topic>Humans</topic><topic>Mental health care</topic><topic>Rats</topic><topic>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - genetics</topic><topic>Schizophrenia - metabolism</topic><topic>Schizophrenia - physiopathology</topic><topic>Thalamus - metabolism</topic><topic>Tranquilizers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kantrowitz, Joshua</creatorcontrib><creatorcontrib>Javitt, Daniel C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kantrowitz, Joshua</au><au>Javitt, Daniel C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glutamatergic transmission in schizophrenia: from basic research to clinical practice</atitle><jtitle>Current opinion in psychiatry</jtitle><addtitle>Curr Opin Psychiatry</addtitle><date>2012-03</date><risdate>2012</risdate><volume>25</volume><issue>2</issue><spage>96</spage><epage>102</epage><pages>96-102</pages><issn>0951-7367</issn><eissn>1473-6578</eissn><coden>COPPE8</coden><abstract>PURPOSE OF REVIEWThe past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.
RECENT FINDINGSWe review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARYAlthough evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>22297716</pmid><doi>10.1097/YCO.0b013e32835035b2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-7367 |
| ispartof | Current opinion in psychiatry, 2012-03, Vol.25 (2), p.96-102 |
| issn | 0951-7367 1473-6578 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5224527 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Animals Antipsychotic Agents - therapeutic use Biomarkers - metabolism Clinical medicine Clinical Trials as Topic Genetics Glutamic Acid - genetics Glutamic Acid - metabolism Humans Mental health care Rats Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenia - genetics Schizophrenia - metabolism Schizophrenia - physiopathology Thalamus - metabolism Tranquilizers |
| title | Glutamatergic transmission in schizophrenia: from basic research to clinical practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T16%3A43%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glutamatergic%20transmission%20in%20schizophrenia:%20from%20basic%20research%20to%20clinical%20practice&rft.jtitle=Current%20opinion%20in%20psychiatry&rft.au=Kantrowitz,%20Joshua&rft.date=2012-03&rft.volume=25&rft.issue=2&rft.spage=96&rft.epage=102&rft.pages=96-102&rft.issn=0951-7367&rft.eissn=1473-6578&rft.coden=COPPE8&rft_id=info:doi/10.1097/YCO.0b013e32835035b2&rft_dat=%3Cproquest_pubme%3E2585551971%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=921331322&rft_id=info:pmid/22297716&rfr_iscdi=true |